Shares of Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report) shot up 1.1% on Wednesday . The stock traded as high as $13.71 and last traded at $13.42. 1,452,967 shares traded hands during trading, an increase of 199% from the average session volume of 486,688 shares. The stock had previously closed at $13.27.
Eliem Therapeutics Price Performance
The stock has a market cap of $411.17 million, a P/E ratio of -26.08 and a beta of -0.39. The stock has a 50-day simple moving average of $11.46 and a 200-day simple moving average of $7.97.
About Eliem Therapeutics
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
Further Reading
- Five stocks we like better than Eliem Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
